| Document |
Document Title |
|
WO/2001/064643A2 |
Benzamide compounds of the formulae (VI) and (VII), where the variables are as defined in the claims, including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalia...
|
|
WO/2001/064826A2 |
The invention relates to catalytically bleaching substrates, especially laundry fabrics, with a bleaching composition and a peroxyl source.
|
|
WO/2001/064655A1 |
Pyrimidine derivatives of the formula (I), wherein: Q¿1? and Q¿2? are independently selected from aryl or carbon linked heteroaryl optionally substituted as defined within; and one or both Q¿1? and Q¿2? are substituted on a ring carb...
|
|
WO/2001/062736A1 |
This invention is directed to compounds of formula (I) and their pharmaceutically acceptable salts, wherein R?1¿, R?2¿, and R?3¿ are as defined herein; intermediates for the synthesis of such compounds, pharmaceutical compositions con...
|
|
WO/2001/062233A2 |
The invention relates to cyclic heteroaromatic compounds, containing at least one nitrogen atom, and to their use in the manufacture of medicaments for the treatment of diseases, related to adenosine receptor modulators, such as Alzheime...
|
|
WO/2001/060814A2 |
The present invention relates to pyrrole substituted 2-indolinone compounds of formula (I): and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefor are expected to be useful in the preventi...
|
|
WO/2001/058884A1 |
According to the novel method, microbicidally active 2-(1,2,4-triazol-1-yl)-ethanols of formula (I), wherein A?1¿, A?2¿, R?1¿, R?2¿, R?3¿ and R?4¿ have the meanings given in the description, are produced by reacting hydrazine deriv...
|
|
WO/2001/057008A1 |
The present invention is directed to a compound of formula (I), racemic-diastereomeric mixtures thereof, optical isomers thereof, prodrugs thereof, isotopes thereof or pharmaceutically-acceptable salts of said compound, isomers, prodrugs...
|
|
WO/2001/055146A1 |
The present invention relates to a compound with aryl-amidines, particularly amidinoaryl-cyclopropanes, amidinoarylmethyl-pyrroles, amidinoaryl-benzenes, amidinoaryl-pyridines, or amindonoaryl-alanines, represented by formula (1), a phar...
|
|
WO/2001/055116A2 |
A compound of formula (I) or a salt, ester, amide or prodrug thereof; R?5¿ is an optionally substituted 6-membered aromatic ring containing at least one nitrogen atom, and R?1¿, R?2¿, R?3¿, R?4¿ are independently selected from halog...
|
|
WO/2001/053263A1 |
Corticotropin-releasing factor (CRF) antagonists having the formulae (I), (II) or (III), wherein the dashed lines, A, B, Y, Z, G, R¿3?, R¿4?, R¿5?, R¿6?, R¿16? and R¿17? are as defined in the application, and processes for preparin...
|
|
WO/2001/053256A1 |
The invention relates to benzoylguanidines of formula (I), wherein R2 stands for -Y-p-(C¿6?H¿4?)-R11, -Y-m-(C¿6?-H¿4?)-R11 or -Y-o-(C¿6?H¿4?)-R11; R11 represents (C¿1?-C¿9?)-heteroaryl, which is bonded by C or N and is substitute...
|
|
WO/2001/053274A1 |
Amide compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction in order to ...
|
|
WO/2001/051473A1 |
The invention relates to 1,2-diaryl benzimidazoles of general formula (I) and to the use of benzimidazole derivatives for producing medicaments utilized for the treatment and prophylaxis of illnesses that are associated with a microglia ...
|
|
WO/2001/051485A1 |
Salts of pyrimidine derivatives are provided having formula (I), wherein R represents hydrogen, methyl or ethyl; Z represents a substituted or unsubstituted 1-piperidinyl, a substituted or unsubstituted 4-morpholinyl, or a substituted or...
|
|
WO/2001/047897A1 |
N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula I. Methods of production, pharmaceutical compositions an...
|
|
WO/2001/047920A1 |
The present invention is related to benzazole derivatives according to formula (I) wherein X is O, S, or NR?O¿ with R?0¿ being H or an unsubstituted or substituted C¿1?-C¿6?alkyl, and G is an unsubstituted or substituted pyrimidinyl ...
|
|
WO/2001/047904A1 |
The invention relates to novel thiazolyl amide derivatives, to a method for producing them and to their use as medicaments, especially as antiviral medicaments.
|
|
WO/2001/047874A1 |
Compounds of formula (I) wherein R is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl or heterocyclyl; and R?1¿ is bicyclyl or heterobicyclyl; are useful in the treatment and prophylaxis of conditions mediated by s-CD23 or TNF.
|
|
WO/2001/047883A1 |
Fused-ring compounds represented by general formula [I] or the like, or pharmaceutically acceptable salts thereof; and hepatitis C remedies containing the compounds or salts: [I] (wherein each symbol is as defined in the description). Th...
|
|
WO/2001/047890A1 |
Compounds effective in the treatment of diseases caused via autophosphorylation of PDGF receptor, particularly compounds useful as intimal thickening inhibitor. Specifically, compounds of the general formula (I) or pharmacologically acce...
|
|
WO/2001/047921A1 |
Compounds that selectively inhibit inappropriate kinase activities and methods for their preparation are disclosed. In one embodiment, the compounds are represented by Formula (I). As selective inhibitors of inappropriate kinase activiti...
|
|
WO/2001/047918A2 |
The invention relates to azolyl-alkyl oxazole and oxadiazole derivatives of the general formula (I), wherein the symbols and indices are defined as follows: R¿1? represents (C¿1?-C¿4?) haloalkyl; R¿2? represents hydrogen, halogen, (C...
|
|
WO/2001/043712A1 |
The invention relates to cosmetic and/or dermatological preparations which contain, in part, novel catechol oximes of formula (I). Said preparations can promote, in physiological systems, the natural defense mechanisms against free radic...
|
|
WO/2001/044208A1 |
The invention relates to compounds of formula (I) and the salts thereof in the optically active form. The respective optically active compound is present as a pure stereo isomer (with R- or S-configuration) with regard to the configurati...
|
|
WO/2001/044241A1 |
The present invention describes compounds of formula (I) and enantiomers, diastereomers and pharmaceutically acceptable salts thereof. The formula (I) compounds are protein kinase inhibitors and are useful in the treatment of proliferati...
|
|
WO/2001/044170A1 |
The invention provides adamantane derivatives of formula (I), a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy. In formula (I)...
|
|
WO/2001/044217A1 |
Compounds of formula (I) and pharmaceutically acceptable salts thereof. As used in formula (I), and throughout the specification, the symbols have the following meanings: R¿1? and R¿2? are independently hydrogen, fluorine or alkyl; R¿...
|
|
WO/2001/042194A1 |
The invention provides adamantane derivatives of formula (I), a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy.
|
|
WO/2001/042199A1 |
An amidinophenylpyruvic acid derivative represented by the following formula, its analogs and pharmaceutically acceptable salts thereof which have an excellent effect of inhibiting activated blood coagulation factor VII.
|
|
WO/2001/040217A1 |
The invention relates to compounds of formula (1) and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R?1¿, R?7¿, R?8¿, R?9¿, R?10¿, and R?11¿ are as defined herein. The invention also relates to method...
|
|
WO/2001/040146A1 |
A process for preparing an ionic liquid or salt, preferably in which the cation comprises an N-alkylated base and the anion is a carboxylate, formed by reaction between an organic base and an alkylating agent, wherein the alkylating agen...
|
|
WO/2001/040163A1 |
Disclosed is a method for preparing a t-butoxycarbonylated amine compound and, more particularly, a method for preparing a t-butoxycarbonylated amine compound where an amine compound is reacted with a t-butylchloroformate in an aqueous o...
|
|
WO/2001/037826A1 |
NPYY5 receptor antagonists which contain compounds represented bygeneral formula (I), prodrugs thereof, pharmaceutically acceptable salts thereof or solvates of the same wherein R?1¿ represents lower alkyl, cycloalkyl, etc.; R?2¿ repre...
|
|
WO/2001/036360A1 |
The invention provides novel selective estrogen receptor modulator compounds of general formula (I), wherein R1 and R2, which are the same or different are a) H, halogen, OCH¿3?, OH; or b) (II), where X is O, NH or S; and n is an intege...
|
|
WO/2001/036403A1 |
Disclosed are novel aromatic compounds of formula (I) wherein G, X, Ar, L and Q are defined herein. The compounds are useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chr...
|
|
WO/2001/034573A1 |
The invention relates to compounds of formula (I) which have anti-Helicobacter pylori activity.
|
|
WO/2001/032652A2 |
N-substituted carbamoyloxyalkyl-azolium derivatives of general formula (I), wherein Q, Y, R?1¿, R?2¿, R?3¿, Y and X?-¿ are as defined in the claims and the description as well as salts, hydrates or solvates thereof. The compounds of ...
|
|
WO/2001/032653A1 |
The present invention is directed to novel heterocyclic substituted pyrazolones, including pharmaceutical compositions, diagnostic kits, assay standards or reagents containing the same, and methods of using the same as therapeutics. The ...
|
|
WO/2001/030761A1 |
The invention relates to heterocyclically substituted benzoylguanidine of formula (I), wherein the substituents R(1) to R(4) have the meanings given in the claims. These compounds (I) are suitable for use as anti-arrhythmic medicaments c...
|
|
WO/2001/030148A1 |
This invention relates to novel substituted succinic acid metallo-$g(b)-lactamase inhibitors which are useful potentiators of $g(b)-lactam antibiotics. Accordingly, the present invention provides a method of treating bacterial infections...
|
|
WO/2001/028996A2 |
Enantiomerically enriched compounds having the absolute stereochemistry of the formula (I) or a pharmaceutically acceptable salt, ester or prodrug thereof, which are useful for inhibiting neuraminidases from disease-causing microorganism...
|
|
WO/2001/029009A1 |
Pyrimidines of formula (1) are described, wherein R?1¿ is a -XR?6¿ group; R?2¿ and R?3¿ which may be the same or different is each a hydrogen or halogen atom or a group selected from an optionally substituted aliphatic, cycloaliphati...
|
|
WO/2001/027081A1 |
The invention relates to a 6-substituted indoline of formula (I), wherein R¿1? to R¿5? and X are as defined in claim 1, isomers and salts of said compound, in particular physiologically compatible salts of said compound having pharmaco...
|
|
WO/2001/027068A1 |
The present invention relates to compounds of formula (I) and to their pharmaceutically acceptable salts. Compounds of formula (I) exhibit activity as serotonin, norepinephrine, and dopanine reuptake inhibitors and can be used in the tre...
|
|
WO/2001/025203A1 |
The present invention relates to novel pyridine carboxamide or sulfonamide derivative compounds of formula (I), wherein R¿1? to R¿6? have the meanings provided herein. The invention further relates to combinatorial libraries containing...
|
|
WO/2001/025229A1 |
Amide compounds of formula (I) wherein R?1¿ is an N-containing heterocyclic group selected from imidazolyl, triazolyl, pyridyl, pyridazinyl, pyrimidinyl and pyrazinyl, each of which may be substituted with one or more lower alkyl groups...
|
|
WO/2001/023362A2 |
Rate-controlled particles, comprising compounds of formula (I) as a solid dispersion.
|
|
WO/2001/021600A1 |
The present invention relates to an isoxazoline derivative of formula (I), the pharmaceutically acceptable salts, esters and stereochemically isomeric forms thereof, and the use of the derivative in inhibiting the activity of caspases. T...
|
|
WO/2001/021602A1 |
Compounds are provided which have structure (I), wherein Q is C or N; A is O or S; Z is O or a bond; X is CH or N and R?1¿, R?2¿, R?2a¿, R?2b¿, R?2c¿, R?3¿, Y, x, m, and n are as defined herein, which compounds are useful as antidi...
|
